Related Experiment Videos
[Empirical antibiotic therapy and ceftazidime]
1Clinique des Maladies infectieuses, Hôpital Saint-Louis, Paris.
Presse Medicale (Paris, France : 1983)
|October 26, 1988
Summary
Ceftazidime effectively treats severe hospital-acquired infections, often alone or in combination therapy. Combining ceftazidime with vancomycin or imidazole derivatives enhances coverage against resistant bacteria and specific pathogens.
Area of Science:
- Infectious Diseases
- Pharmacology
- Bacteriology
Context:
- Ceftazidime is a key antibiotic for severe hospital-acquired infections.
- It serves as an alternative to aminoglycosides and combination therapies.
- Clinical scenarios necessitate combination therapy for comprehensive coverage.
Purpose:
- To outline the primary indications for ceftazidime use.
- To detail situations requiring combination therapy with vancomycin or imidazole derivatives.
- To highlight the synergistic benefits of ceftazidime-aminoglycoside combinations.
Summary:
- Ceftazidime is indicated for empirical treatment of severe and hospital-acquired infections.
- It can be used as monotherapy or in combination with vancomycin (for Staphylococci/Enterococci) or imidazole derivatives (for anaerobes).
- Combination with aminoglycosides offers synergistic bactericidal activity, prevents resistance, and is recommended for difficult-to-reach infections or immunocompromised patients.
Impact:
- Optimizes antibiotic selection for severe infections.
- Provides strategies to combat multidrug-resistant organisms.
- Improves patient outcomes in critical care settings.